Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Riviciclib||P276-00|P276||CDK1 Inhibitor 13 CDK4 Inhibitor 12 CDK9 Inhibitor 16||Riviciclib (P276-00) is an inhibitor of CDK1, CDK4, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 17363486, PMID: 32175313).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Riviciclib||Phase I||Actionable||In a Phase I study, P276-00 demonstrated safety and some preliminary efficacy in patients with advanced solid tumors ( J Clin Oncol (Meeting Abstracts) June 2007 vol. 25 no. 18_suppl 14117).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|